Last Updated : May 14, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | eplontersen | Polyneuropathy in hereditary transthyretin-mediated amyloidosis | Active | |||
Alecensaro | alectinib | ALK-positive NSCLC | Active | |||
Adcetris | Brentuximab vedotin | Hodgkin lymphoma | Active | |||
Carvykti | ciltacabtagene autoleucel | Relapsed or refractory multiple myeloma | Active | |||
TBC | leniolisib | Activated phosphoinositide 3 kinase delta syndrome | Active | |||
TBC | avapritinib | Advanced Systemic Mastocytosis | Active | |||
N/A | enzalutamide | Genito-urinary cancer (prostate cancer) | Open for Stakeholder Input | |||
TBC | talquetamab | Relapsed or refractory multiple myeloma | Received | |||
Breyanzi | lisocabtagene maraleucel | Relapsed or refractory large B-cell lymphoma | Received | |||
Ferinject | ferric carboxymaltose | Iron deficiency anemia | Received |